Immunotherapy for lung cancer gives hope to lung cancer patients

The cancer drug Opdivo (nivolumab) may offer hope of a longer life for some patients with advanced lung cancer, a new small study finds.

Currently, only about 5 percent of patients with advanced non-small-cell lung cancer survive five years or more. But that rate rose to about 16 percent among a group taking Opdivo

Opdivo is an immunotherapy drug, which means it enlists the patient’s own immune system to fight diseases such as cancer.

Read the article: http://health.usnews.com/health-care/articles/2017-04-04/drug-offers-some-hope-for-a-deadly-lung-cancer